|Systematic (IUPAC) name|
|AHFS/Drugs.com||UK Drug Information|
|S.C.; I.M.; I.V.; subcutaneous implant; intranasal|
|Biological half-life||0.8–1.7 hours (48–102 minutes)|
|ATC code||D02BB02 (WHO)|
|Synonyms||Melanotan; Melanotan-1; Melanotan I; CUV1647; EPT1647; NDP-MSH; NDP-α-MSH; [Nle4,D-Phe7]α-MSH|
|Molar mass||1646.845 g/mol|
|(what is this?)|
- Note: this article describes afamelanotide which is also known by the name melanotan I. afamelanotide should not be confused with melanotan II.
Afamelanotide (i// (INN) (brand name Scenesse), also known as melanotan I (or melanotan-1), originally developed at the University of Arizona and now by Clinuvel Pharmaceuticals, is a synthetic peptide and analogue of the naturally occurring melanocortin peptide hormone α-melanocyte stimulating hormone (α-MSH) that has been shown to induce the production of darkening dermal pigmentation through melanogenesis and thereby subsequently reduce sun (UV) damage to UV light-exposed skin in preliminary research and human clinical trials. Its amino acid sequence is Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, and it is additionally known as [Nle4,D-Phe7]-α-MSH, which is sometimes abbreviated as NDP-MSH or NDP-α-MSH (especially in the scientific literature).
Afamelanotide is the International Nonproprietary Name for the molecule [Nle4,D-Phe7]α-MSH initially researched and developed as melanotan-1 i// and later, CUV1647 (by Clinuvel). A marketing trade name for one brand of afamelanotide was approved in 2010 by the European Medicines Agency (EMA) Name Review Group (NRG) and the agency's Committee for Medicinal Products for Human Use (CHMP) as Scenesse (pronounced "sen-esse"). On May 5, 2010 the Italian Medicines Agency (AIFA, or Agenzia Italiana del Farmaco) became the first governmental health organization ever (even before the drug received approval in Europe) to authorize afamelanotide as a medicine for therapeutic treatment of Italian citizens to reduce painful dermal photosensitivity stemming from the orphan disease erythropoietic protoporphyria (EPP). This approval allowed the drug to be immediately available for prescription in Italy and reimbursable under the country's national health system. Authorities in Switzerland have also allowed prescription of the drug for EPP with reimbursement approved by two unnamed insurers. Afamelanotide is currently being trialed in the form of a "grain of rice"-sized bioabsorbable subcutaneous implant as a potential therapeutic photoprotection-inducing agent for a series of light-related skin indications as well as a potential dermal repigmentation agent for vitiligo. Afamelanotide, as of October 24, 2014, has been approved by the EMA in Europe for the treatment of EPP. Clinuvel now intends to seek approval of afamelanotide in the United States.
Unlicensed and untested powders sold as "melanotan" are found on the Internet and are reported to be used by tens of thousands of members of the general public for sunless tanning. Multiple regulatory bodies have warned consumers that the peptides may be unsafe and ineffective in usage, with one regulatory agency warning that consumers who purchase any product labeled "melanotan" risk buying a counterfeit drug. Clinuvel Pharmaceuticals, the developer of afamelanotide, and medical researchers have warned consumers that counterfeit products sold using the names "melanotan I and II", could "pose a hazard to public health". Clinuvel has stated publicly that products sold online as "melanotan" are not afamelanotide.
- 1 Historical development
- 2 Pharmacology
- 3 Preclinical studies relative to carcinogenicity
- 4 Human dermal pigmentation clinical trials
- 5 Therapeutic clinical trials
- 6 General population usage of melanotan peptides
- 7 See also
- 8 References
- 9 External links
[Nle4,D-Phe7]-α-MSH was first synthesized at the University of Arizona. Researchers there knew that one of the best defenses against skin cancer was melanin activated in the skin, a tan. They hypothesized that an effective way to reduce skin cancer rates in people would be to induce the body's natural pigmentary system to produce the body's natural photoprotective skin pigmentation (a tan) prior to UV exposure. The body's naturally occurring hormone α-MSH causes melanogenesis, a process by which the skin's pigment cells (melanocytes) produce the skin's pigment (melanin). They tested to see if administering this endogenous hormone to the body directly could be an effective means of sunless tanning. What they found was that while it appeared to work, natural α-MSH had too short a half life in the body to be practical as a therapeutic drug. The team then searched for a more potent and stable alternative.
After synthesizing and screening hundreds of molecules, the researchers, headed by Victor J. Hruby and Mac E. Hadley, found a peptide, [Nle4,D-Phe7]-α-MSH, that was approximately 1,000 times more potent than natural α-MSH. They dubbed this new peptide molecule "Melanotan" (later Melanotan-1, now known as afamelanotide). They subsequently developed another analog, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2), which they called "Melanotan II". The scientists hoped to use these peptides to prevent melanoma by stimulating the body's natural pigmentary mechanism to create a tan without exposure to harmful levels of UV radiation. This in turn, they hypothesized, could reduce the potential for skin damage in the tanning population that could lead to skin cancer.
The scientists licensed their patented peptides, via a technology transfer company, to a number of biotechnology companies intent on developing them into drugs. Afamelanotide (formerly the proprietary CUV1647) has been tested, in an implant delivery formulation, and clinically trialed by the Australian company Clinuvel Pharmaceuticals, for a series of conditions affecting the skin including erythropoietic protoporphyria (EPP), polymorphous light eruption (PMLE), solar urticaria (SU), phototoxicity associated with systemic photodynamic therapy and actinic keratosis (AK) and squamous cell carcinoma skin cancer in patients who have received organ transplants, vitiligo and Hailey Hailey disease. The drug has previously been tested in polymorphous light eruption (PMLE), solar urticaria (SU) and phototoxicity associate with systemic photodynamic therapy.
As an analogue of α-MSH, the mechanism of action of afamelanotide is biomimicry of the natural mammalian tanning process. Afamelanotide produces its photoprotective effects by triggering a 'signaling cascade' via activation of the MC1 receptor on melanin-producing cells known as melanocytes. Upon afamelanotide binding with the MC1 receptor on the surface of melanocytes in the epidermal layer of the skin, it begins a series of actions and reactions that result in melanocytes favoring the production of eumelanin (photoprotective black/brown pigment) over pheomelanin (red/yellow pigment).
The initial binding activates the MC1 receptor leading to the activation of adenylate cyclase (AC) and stimulation of the production of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). cAMP in turn activates protein kinase A (PKA) resulting in the phosphorylation of the cAMP response element-binding (CREB). Phosphorylated CREB will bind to the cAMP response element (CRE) on the microphthalmia-associated transcription factor (MITF) gene leading to the synthesis of the MITF protein. MITF has the ability to activate several genes by binding to them, including the MC1 receptor gene and the genes involved in melanogenesis (tyrosinase, TYRP1 and DCT, which encode enzymes of the same names). This results in increased concentrations of the melanogenic enzymes within the melanocyte. It is the levels of these enzymes within a melanocyte that determines whether the cell will create eumelanin instead of pheomelanin.
Production of eumelanin rather than pheomelanin by melanocytes, thereby increases pigmentation of the skin and thus provides photoprotection against harmful UV radiation from the sun. This is the intended therapeutic benefit from the medicinal administration of afamelanotide.
In addition to its pigmenting effects, afamelanotide has been found to induce brain-derived neurotrophic factor (BDNF) expression in the rodent brain via activation of the MC4 receptor and mediate "intense" neurogenesis and cognitive recovery in an animal model of Alzheimer's disease.
Preclinical studies relative to carcinogenicity
Owing to [Nle4,D-Phe7]α-MSH being a superpotent synthetic form of α-MSH concerns were present in the minds of the original researchers as to it possibly having the potential to cause melanocytes to turn malignant or to enhance the proliferation of pre-existing melanomas and possibly other skin cancer types. These concerns led the researchers to conduct a series of preclinical studies to examine the carcinogenic potential that [Nle4,D-Phe7]α-MSH had in both in vivo and in vitro skin models. According to the researchers these studies established a, "lack of carcinogenic potential for melanotan". Further studies reported that [Nle4,D-Phe7]α-MSH did not enhance anchorage-independent clonogenic cell growth, a hallmark of malignancy, and it had no effect on tumor incidence, size or on metastatic spread in in vitro and animal models. Instead, one study reported that [Nle4,D-Phe7]α-MSH actually inhibited melanoma cell proliferation in vitro.
Human dermal pigmentation clinical trials
A 1991 study of [Nle4,D-Phe7]α-MSH in 28 "healthy white men" who used a "high-potency sunscreen during the trial" concluded that "Human skin darkens as a response to a synthetic melanotropin given by subcutaneous injection. Skin tanning appears possible without potentially harmful exposure to ultraviolet radiation."
A 1997 pharmacokinetic trial to establish efficacy of peptide administration compared intravenous, oral and subcutaneous routes. The study found that, "subcutaneous administration is an efficacious method of delivering melanotan".
A 1999 clinical dose ranging study in "eight male volunteers with 'tannable' skin types III-IV" given [Nle4,D-Phe7]α-MSH (Melanotan-I) determined that an optimal dose for ten daily subcutaneous injections is 0.16 mg/kg per day.
A 2000 study to determine increases of eumelanin expression in seven, "normal volunteers" administered [Nle4,D-Phe7]α-MSH concluded that, "the tanning induced by Melanotan in the face and forearm is associated with a significant increase in the eumelanin content of the human skin."
Three 2004 Phase I clinical trials sought to establish the safety of [Nle4,D-Phe7]α-MSH therapy combined with UV-B light or sunlight exposure. The researchers determined, "Melanotan-1 can be safely combined with UV-B light or sunlight and appears to act synergistically in the tanning response to light." These trials were funded by the National Cancer Institute.
A 2003 Phase IIb clinical human trial demonstrated in a group of seventy-nine volunteers that those who were administered [Nle4,D-Phe7]α-MSH daily for a period of three months had highly significant increases in skin-melanin while those who were not, did not. It found fairer-skin people (Fitzpatrick Types I/II) recorded increases in melanin of up to 100% in some areas and that their risk of sunburn injury was reduced by more than 50%. This trial, results from which were published in the British Journal of Dermatology, showed that the drug increased the minimal urticarial dose of light required to onset urticarial reactions. Clinuvel announced that it was deferring the solar urticaria program in February 2010.
A 2006 study Phase II clinical trial were completed assessing afamelanotide's ability [Nle4,D-Phe7]α-MSH's effect on melanin synthesis in humans with MC1 receptor-variant alleles. Researchers found that "MELANOTAN effectively increases the melanin content of skin in those individuals with MC1R variant alleles and therefore, those most in need of photoprotection." Results, released in December 2009, showed that seven of nine patients treated with afamelanotide could tolerate ambient light exposure and had an improve quality of life after 60 days of treatment.
Therapeutic clinical trials
Afamelanotide is being trialed by Clinuvel as a drug for photoprotection for five indications:
- Erythropoietic protoporphyria
- Polymorphous light eruption
- Phototoxicity associated with systemic photodynamic therapy
- Solar urticaria
- Actinic keratosis and squamous cell carcinoma skin cancer in patients who have received an organ tranplant
Clinuvel is also trialing the drug as a potential dermal repigmentation agent for the treatment of vitiligo.
Phase II trials of afamelanotide in erythropoietic protoporphyria (EPP) were completed in February 2007. These results, published in the New England Journal of Medicine in 2009, showed that EPP patient's "tolerance to artificial light and melanin density increased significantly by day 120 after the start of afamelanotide, to 11 times and 1.3 times the baseline values".
Phase III trials of afamelanotide as a treatment for EPP commenced in June 2007. These trials were to determine if afamelanotide "could reduce the number and severity of phototoxic reactions in patients with erythropoietic protoporphyria" and "increase the duration of exposure to sunlight that can be tolerated by EPP patients".
In January 2009, interim results were released from the Phase III trial involving 14 patients from a clinic in Zurich. These results showed that "the severity of phototoxic reaction for patients with the disease was significantly reduced".
In December 2012, Phase III trial results showed that EPP patients receiving afamelanotide “experienced half as many phototoxic reactions” as patients on placebo and spent more time in sunlight. Results also showed that patients taking afamelanotide experienced less severe phototoxic reactions and had an improved quality of life after receiving the drug.
The EMA, Swissmedic, Therapeutic Goods Administration and the U.S. Food and Drug Administration have recognized afamelanotide as an orphan drug for the treatment of EPP and congenital erythropoietic porphyria.
Polymorphous light eruption
Phase II trials of afamelanotide in polymorphous light eruption (PLE) were completed in August 2006. The trials reported that patients treated with the drug "used significantly less systemic corticosteroids" and reported "fewer episodes of PLE" compared to those treated with a placebo. Phase III trials commenced in January 2007, and completed 2009 with preliminary results released in December 2009. Final results were never released.
Skin cancer, solar urticaria and phototoxicity with photodynamic therapy
|This section is missing information about the results of completed phase II trials to reduce the prevalence of actinic keratoses and squamous cell carcinoma skin cancers in patients who have received organ transplants. (September 2015)|
Phase II trials are underway to assess afamelanotide's ability to reduce the prevalence of actinic keratoses and squamous cell carcinoma skin cancers in patients who have received organ transplants. These patients suffer greater numbers of skin cancers as they are immunosuppressed. Trials commenced in November 2007. Final results are expected late 2013.
Phase II trials assessing afamelanotide as a preventative treatment in patients suffering solar urticaria commenced in September 2008.
Phase II trials are underway to assess afamelanotide's ability to prevent photosensitivity in patients who have undergone systemic photodynamic therapy (PDT), a cancer treatment where patients are given a light-sensitising drug. Trial completed, however results never released.
General population usage of melanotan peptides
General public users of the melanotan peptides (including melanotan-1) have been reported to number into the tens of thousands in the UK with one BBC report explaining that a January 2009 straw poll by the reporting journalist of just 6 UK needle exchanges revealed, "nearly 500 people wanting the syringes [for peptide usage] or information about melanotan". Academic researchers have reported on a "thriving" internet community of users of the peptides at the site Melanotan.org where members discuss their experiences using the unlicensed and unregulated drugs. In May 2010 the Norwegian tabloid daily Verdens Gang published a story based upon a report by the Norwegian Pharmacy Association stating that 10,000 syringes are sold annually to Norwegian users of melanotan-1 and melanotan II.
"Melanotan" products sold for human use
A number of products are sold online and in gyms and beauty salons as "melanotan" or "melanotan-1" which purport to have the same chemical make up as afamelanotide, of which the visual effect resulting from usage has been noted in an article by Wired.com as being "eerily similar to results obtained in trials at the University of Arizona or by Clinuvel". The Wired.com article explained that these products were Melanotan II, "a similar (but not identical) compound" and Clinuvel has stated that products sold as "melanotan" are "wholly unrelated to Clinuvel's proprietary afamelanotide". Chemicals sold as "melanotan" are not illegal to import, use or own; however their domestic sales (non-export) and supply for human use outside of government sanctioned clinical trials is illegal within the boundaries of certain jurisdictions, including the UK and Australia.
A 2009 paper on unlicensed "melanotan" products, sold on the internet, has reported that long term use of the products can cause moles to darken and increase in size. Academic researchers at Liverpool John Moores University specialized in performance-enhancing drugs published an editorial in the British Medical Journal suggesting that long term use of 'melanotan I and II', "could damage the immune systems as well as triggering other problems".
Health warnings on "melanotan" products sold for human use
Clinuvel has warned consumers against the use of what it terms are "counterfeit", drugs sold as "melanotan I and II" that are promoted by citing research on afamelanotide.
On August 8, 2008 the Danish Medicines Agency (DMA) issued a warning against the use of any product called "Melanotan" purchased on the internet, noting that claims that imply that it has an "effect" for protection against skin cancer "has not been documented".
The UK Medicines and Healthcare products Regulatory Agency issued a similar warning on November 17, 2008 stating that "We are warning people not to use this product. Don't be fooled into thinking that Melanotan offers a shortcut to a safer and more even tan. They are unlicensed in the UK. If you have used either of these products do not use them again and if you have any concerns you should seek advice from your doctor."
The FDA issued a Warning Letter to an online vendor in January 2009 selling "Melanotan ONE" as advertisements of the products on their website were in breach of the Federal Food, Drug, and Cosmetic Act as the site was selling "new drug" products.
The Irish Medicines Board (IMB) issued a precautionary safety alert on February 27, 2009 regarding the use of "the unauthorised medicine Melanotan (I and II)", sold as a powder for injection, stating that "Melanotan is not yet authorised in Ireland and therefore the IMB cannot guarantee the efficacy, safety or quality of this product." In its release, the IMB announced that its tests had found the presence of microbial contamination in a vial of water sold together with melanotan powder which "would expose recipients to a risk of serious infection".
The Norwegian Medicines Agency has issued warnings in 2007 and 2009 about the use of "Melanotan" sold online, while a spokesman for the Australian Therapeutic Goods Administration warned consumers to be "very wary" of using it.
- Ugwu SO, Blanchard J, Dorr RT, et al. (April 1997). <259::AID-BDD20>3.0.CO;2-X "Skin pigmentation and pharmacokinetics of melanotan-I in humans". Biopharmaceutics & Drug Disposition. 18 (3): 259–69. doi:10.1002/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X. PMID 9113347.
- "UA-developed afamelanotide shows promise in rare skin disorder". Arizona University. Retrieved 16 July 2013.
- "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization. 2009. Retrieved 2009-03-02.
- "Clinuvel's Former Tan Drug Succeeds in Porphyria Trial.". BioWorld Today. 2010. Retrieved 2010-08-02.
- "Clinuvel Unveils SCENESSE(R) Following European Brand Approval". Medical News Today. 2010. Retrieved 2010-07-25.
- "Melanotan.org – Publishing information about the Melanotan peptides since June 14, 1999.". Melanotan.org. 2010. Archived from the original on 25 July 2010. Retrieved 2010-07-25.
- "GAZZETTA UFFICIALE: SOMMARIO". Agenzia Nazionale Stampa Associata. 2010. Retrieved 2010-05-17.
- "Clinuvel gets pre-approval win in Italy". Australian LifeScientist. 2010. Archived from the original on 1 June 2010. Retrieved 2010-05-17.
- Sara Hammond (5 November 2014). "Skin Disease Drug Finally Wins Approval". University of Arizona.
- "Melanotan Powder for Injection". Notice Information: – Warning – 27 February 2009. Irish Medicines Board. 2009. Retrieved 2009-02-02.
- "Melanotan – farlig og ulovlig brunfarge". Norwegian Medicines Agency. 2009-01-23. Archived from the original on 17 April 2009. Retrieved 2009-03-11.
- Clinuvel Position Statement on counterfeit products. February 10, 2009.
- "Clinuvel Newsletter – February 2009" (PDF). Clinuvel Pharmaceuticals. 2009-02-26. Retrieved 2009-03-04.
- Kolata, Gina (1987-11-24). "Futuristic Treatments For the Hair and Skin". The New York Times. Retrieved 2010-04-20.
- "UA-developed synthetic hormones speed a tan". Arizona Daily Star. 2006. Retrieved 2009-07-26.
- "The Barbie Drug". Campbell Live, TV3. 2007. Archived from the original (FLV) on 2011-10-04. Retrieved 2007-09-16.
- Christian Mahne (2002-09-04). "Implant offers tanning revolution" (RealVideo). BBC. Retrieved 2009-07-26.
- Christian Mahne (2002-09-04). "Implant offers tanning revolution". BBC. Retrieved 2009-07-26.
- "Competitive Technologies Licenses Additional Patent to Melanotan Corporation, Receives Additional Shares of Epitan". Business Wire. 2005-07-26. Retrieved 2008-08-22.
- "Want a nice tan? Just take a pill" (Flash Video). TV3 (New Zealand). 2009. Retrieved 2009-01-22.
- "SCENESSE's Mechanism of Action". Clinuvel. Retrieved 16 July 2013.
- Schiöth, Helgi B; Mutulis, Felikss; Muceniece, Ruta; Prusis, Peteris; Wikberg, Jarl E S (1998). "Discovery of novel melanocortin4receptor selective MSH analogues". British Journal of Pharmacology. 124 (1): 75–82. doi:10.1038/sj.bjp.0701804. ISSN 0007-1188.
- Giuliani D, Neri L, Canalini F, Calevro A, Ottani A, Vandini E, Sena P, Zaffe D, Guarini S (2015). "NDP-α-MSH induces intense neurogenesis and cognitive recovery in Alzheimer transgenic mice through activation of melanocortin MC4 receptors". Mol. Cell. Neurosci. 67: 13–21. doi:10.1016/j.mcn.2015.05.004. PMID 26003413.
- Ramírez D, Saba J, Carniglia L, Durand D, Lasaga M, Caruso C (2015). "Melanocortin 4 receptor activates ERK-cFos pathway to increase brain-derived neurotrophic factor expression in rat astrocytes and hypothalamus". Mol. Cell. Endocrinol. 411: 28–37. doi:10.1016/j.mce.2015.04.008. PMID 25892444.
- Mac E. Hadley; Robert T. Dorr (April 2006). "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.". Peptides. 27 (4): 921–30. doi:10.1016/j.peptides.2005.01.029. PMID 16412534.
- Meyskens Jr., FL. (1980). "Human melanoma colony formation in soft agar. In: Cloning of Human Tumor Stem Cells". Prog Clin Biol Res. 48: 85–99. PMID 7208529.
- Gehlsen KR; Hadley ME; Levine N; Ray CG; Hendrix MJC. (Nov 1992). "Effects of a melanotropic peptide on melanoma cell growth, metastasis, and invasion.". Pigment Cell Res. 5 (5): 219–23. doi:10.1111/j.1600-0749.1992.tb00540.x. PMID 1337602.
- Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MH, Dorr RT, Johnson CS, et al. (Jun 1997). "Human tumor models in the severe combined immune deficient (scid) mouse.". Cancer Chemother Pharmacol. 40 (3): 209–14. doi:10.1007/s002800050648. PMID 9219503.
- Jiang J, Sharma SD, Nakamura S, Lai JY, Fink JL, Hruby VJ, et al. (Dec 1995). "The Melanotropic Peptide, [Nle4, d-Phe7]α-MSH, Stimulates Human Melanoma Tyrosinase Activity and Inhibits Cell Proliferation.". Pigment Cell Res. 8 (6): 314–323. doi:10.1111/j.1600-0749.1995.tb00680.x. PMID 8789740.
- Levine N, Sheftel SN, Eytan T, et al. (Nov 1991). "Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin". Journal of the American Medical Association, (JAMA). 266 (19): 2730–6. doi:10.1001/jama.266.19.2730. PMID 1658407.
- Ugwu SO, Blanchard J, Dorr RT, et al. (Apr 1997). "Skin pigmentation and pharmacokinetics of melanotan-I in humans". Biopharm Drug Dispos. 18 (3): 259–69. doi:10.1002/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X. PMID 9113347.
- Levine N, Dorr R, Ertl G, Brooks C, Alberts D (Jun 1999). "Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-1) on tanning: a dose-ranging study". Journal of Dermatological Treatment. 10 (2): 127–32. doi:10.3109/09546639909056014.
- Dorr RT, Dvorakova K, Brooks C, et al. (Oct 2000). "Increased eumelanin expression and tanning is induced by a superpotent melanotropin [[Nle4, D-Phe7]-α-MSH in humans". Photochem Photobiol. 72 (4): 526–32. doi:10.1562/0031-8655(2000)072<0526:IEEATI>2.0.CO;2. PMID 11045725.
- Dorr RT, Ertl G, Levine N, et al. (Jul 2004). "Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers". Archives of Dermatology. 140 (7): 827–35. doi:10.1001/archderm.140.7.827. PMID 15262693.
- "Suntan could come 'in an implant'". BBC News. 2003-12-03. Retrieved 2008-10-12.
- "Sunburn Trial Results Show Drug Can Reduce Sun Damage by 50% for Fair-Skinned People, says Trial Head". innovations report. 2003. Archived from the original on 16 September 2008. Retrieved 2008-08-22.
- Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM (Feb 2006). "Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles". Peptides. 27 (2): 388–94. doi:10.1016/j.peptides.2004.12.038. PMID 16293341.
- "Tackling skin cancer in organ transplant patients". Australian Life Scientist. 2007-04-13. Retrieved 2009-04-05.
- "Clinuvel: Successfully tanning vampires". BiotechnologyNews.net. 2007-02-27. Retrieved 2009-03-04.
- Harms J, Lautenshlager S, Minder CE, Minder EI (Jan 2009). "An α-Melanocyte–Stimulating Hormone Analogue in Erythropoietic Protoporphyria". New England Journal of Medicine. 360 (3): 306–307. doi:10.1056/NEJMc0805682. PMID 19144952.
- "Clinuvel gets early nod on sun drug". Australian Life Scientist. 2007-06-12. Retrieved 2009-03-04.
- "Positive results for Clinuvel's drug trial". The Australian. 2009-01-22. Retrieved 2009-03-04.
- "EMA grants Clinuvel two orphan drug designations". Biospectrum Asia. 2008-03-12. Retrieved 2009-03-04.
- "US orphan designation for Clinuvel". Biospectrum Asia. 2008-04-29. Retrieved 2009-03-04.
- "Orphan drugs". Therapeutic Goods Administration (TGA). Australian Government Department of Health. 7 April 2015. Retrieved 17 April 2015.
- "US orphan designation for Clinuvel". BioTechnologyNews.Net. 2008-07-29. Retrieved 2009-03-04.
- "Clinuvel positive Phase 2". BioTechnologyNews.Net. 2008-08-29. Retrieved 2009-03-04.
- "Clinuvel moves to phase III for PLE". Australian Life Scientist. 2007-01-25. Retrieved 2009-03-04.
- "New trial target for Clinuvel's suntan drug". BiotechnologyNews.net. 2007-11-01. Retrieved 2009-03-04.
- "Ethics approval for sun drug in sunny Manchester". BiotechnologyNews.net. 2008-06-12. Retrieved 2009-03-04.
- "Clinuvel launches new Phase 2". BiotechnologyNews.net. 2008-09-23. Retrieved 2009-03-04.
- "Illegal Tanning drugs sold" (Windows Media Video). Inside Out, BBC. 2009-01-14. Retrieved 2009-07-23.
- "Believe It Or Not 'Tanorexia' A Very Real Problem". WCBS-TV, CBS. 2009-05-20. Archived from the original (Flash Video) on May 21, 2009. Retrieved 2009-07-23.
- "Fools Gold". Cosmopolitan (Australia). 2009-06-14. Retrieved 2009-07-25.
- Kim Mulvihill (2009-03-05). "'Barbie drug' promises instant tan without sun damage". KSL-TV, NBC. Archived from the original (Flash Video) on 4 June 2011. Retrieved 2015-10-20.
- Flåm, Karoline (2010-05-29). "Apoteket selger årlig 10.000 sprøyter til barbie-dopet". Norway: Verdens Gang. Archived from the original on 27 July 2010. Retrieved 2010-07-08. (Norwegian)
- Madrigal, Alexis (2009-01-29). "Suntan Drug Greenlighted for Trials". Wired. Archived from the original on 5 May 2009. Retrieved 2009-04-11.
- "Tanning drug a health risk". Herald Sun. 2009-10-31. Retrieved 2009-10-31.
- Ewan A Langan; Z. Nie; Lesley E Rhodes (June 2010). "Melanotropic peptides: More than just "Barbie drugs" and "sun tan jabs?"". British Journal of Dermatology. 163 (3): 451–5. doi:10.1111/j.1365-2133.2010.09891.x. PMID 20545686.
- Ewan A Langan; Denise Ramlogan; Lynne A Jamieson; Lesley E Rhodes (January 2009). "Change in moles linked to use of unlicensed "sun tan jab"". BMJ. 388: b277. doi:10.1136/bmj.b277. PMID 19174439.
- "Worry over tan jab mole changes". BBC. 2009-01-28. Archived from the original on 31 January 2009. Retrieved 2009-03-04.
- Devlin, Kate (2009-01-27). "Illegal tanning drug can change appearance of moles, scientists warn". London: The Daily Telegraph. Retrieved 2009-03-04.
- "Risky tan jab warnings 'ignored'". BBC. 2009-02-18. Archived from the original on 21 February 2009. Retrieved 2009-03-04.
- "Warning against the product Melanotan". Danish Medicines Agency. 2008. Retrieved 2008-08-11.
- ""Tan jab" is an unlicensed medicine and may not be safe". MHRA. 2008. Retrieved 2008-11-17.
- "US Lab Research Inc Warning letter". U.S. Food and Drug Administration. 2009-01-29. Archived from the original on 10 July 2009. Retrieved 2009-07-23.
- "Legemiddelverket advarer mot bruk av Melanotan". Norwegian Medicines Agency. 2007-12-13. Archived from the original on 17 April 2009. Retrieved 2009-03-11.